格尼C的分子有效性作为对瘤抵抗性前列腺癌的双重向疗法
Gisella Campanelli1, Rabab Al Deabel2, Anand Puaar1
1Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY, USA.
Molecular nutrition & food research
|October 20, 2023
概括
结合恩扎胺 (Enz) 的格内丁C (GnC) 有效向基受体 (AR) 和转移相关蛋白1 (MTA1) 在基抗性前列腺癌 (CRPC) 中. 这种组合疗法通过抑制瘤进展来治疗晚期CRPC具有前途.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 阴道抗性前列腺癌 (CRPC) 经常通过受体结合变体 (AR-V7) 表达对恩扎胺 (Enz) 的耐药性.
- 非AR驱动的信号通路,包括转移相关蛋白1 (MTA1) 的过度表达,也会导致CRPC的进展.
- 自然化合物在与常规抗癌药物相结合时提供潜在的协同效应,可能提高疗效并降低毒性.
研究的目的:
- 研究格尼C (GnC) 作为单一疗法和与Enz结合对抗CRPC的体外和体内抗癌作用.
- 阐明组合治疗效果背后的分子机制,重点关注AR和MTA1信号通路.
主要方法:
- 试验室评估包括使用22Rv1CRPC细胞的细胞活力,克隆性存活率和迁移试验.
- 分析了AR和MTA1的表达水平,使用西部斑块,RT-PCR和免疫组织化学 (IHC).
- 在临床前模型中,通过使用生物发光成像进行瘤生长评估来评估体内疗效.
主要成果:
- 单独或与Enz结合使用的Gnc显著抑制了22Rv1细胞中的细胞活力,克隆性存活率和迁移.
- 联合治疗有效抑制了AR和MTA1的表达.
- 在体内研究表明,GnC和Enz联合治疗抑制了瘤增殖和血管生成,同时诱导了亡.
结论:
- 单独和与恩扎胺结合的Gnetin C显示出在抑制晚期CRPC中AR和MTA1驱动的瘤进展方面具有显著的潜力.
- 这种组合疗法代表了一种有前途的新型治疗策略,用于管理割抗性前列腺癌.
关键词:
在 22Rv1 细胞中,在AR-V7中使用AR-V7.格尼丁C 网 C 网 是一种在MTA1中,它是MTA1.组合疗法治疗组合治疗.酵素胺胺的使用方法来自植物的多醇.前列腺癌是前列腺癌.异国移植 异国移植更多相关视频
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
13.1K
06:54MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
11.3K
相关概念视频
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
02:38Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K